Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims : To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting. Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response. Results: Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved the end of treatment response, and 98.1% (202/206) achieved sustained virologic response at 12 weeks post-treatment (SVR12). According to liver function, the SVR12 rates were 99.3% (135/136) in chronic hepatitis, 96.4% (53/55) in compensated cirrhosis, and 100% (6/6) in decompensated cirrhosis. The SVR12 rates according to the genotype were 98.2% (167/170) for genotype 1 and 97.2% (35/36) for genotype 2. An 8-week LDV/SOF treatment in treatment-naïve chronic hepatitis patients with HCV RNA < 6,000,000 IU/mL at baseline resulted in 100% (23/23) SVR12 rates. Overall, LDV/SOF was tolerated well, with a 0.7% (2/273) discontinuation rate due to adverse events that were unrelated to LDV/SOF. Conclusions: LDV/SOF is effective and safe for treating HCV-infected Korean patients with high SVR12 rates.
Abstract
Background/Aims : To evaluate the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) therapy in hepatitis C virus (HCV)-infected Korean patients in a real clinical setting. Methods: A total of 273 patients who received LDV/SOF therapy between May 2016 and February 2021 were consecutively enrolled and analyzed. A per-protocol analysis was performed to evaluate the virologic response. Results: Seventy-five percent were infected with genotype 1, and 25% were infected with genotype 2. A hundred eightyone (66.3%) patients had chronic hepatitis, 74 (27.1%) had compensated cirrhosis, eight (2.9%) had decompensated cirrhosis, and 10 (3.7%) had undergone liver transplantation. Undetectable HCV RNA at week 4 was achieved in 90.2% (231/256) of patients, 99.2% (250/252) achieved the end of treatment response, and 98.1% (202/206) achieved sustained virologic response at 12 weeks post-treatment (SVR12). According to liver function, the SVR12 rates were 99.3% (135/136) in chronic hepatitis, 96.4% (53/55) in compensated cirrhosis, and 100% (6/6) in decompensated cirrhosis. The SVR12 rates according to the genotype were 98.2% (167/170) for genotype 1 and 97.2% (35/36) for genotype 2. An 8-week LDV/SOF treatment in treatment-naïve chronic hepatitis patients with HCV RNA < 6,000,000 IU/mL at baseline resulted in 100% (23/23) SVR12 rates. Overall, LDV/SOF was tolerated well, with a 0.7% (2/273) discontinuation rate due to adverse events that were unrelated to LDV/SOF. Conclusions: LDV/SOF is effective and safe for treating HCV-infected Korean patients with high SVR12 rates.
참고문헌 (41)
- Messina JP, "Global distribution and prevalence of hepatitis C virus genotypes", Hepatology, 61, pp.77~87 (2015)
- Niederau C, "Prognosis of chronic hepatitis C : results of a large, prospective cohort study", Hepatology, 28, pp.1687~1695 (1998)
- Polaris Observatory HCV Collaborators, "Global prevalence and genotype distribution of hepatitis C virus infection in 2015 : a modelling study", Lancet Gastroenterol Hepatol, 2, pp.161~176 (2017)
- European Association for the Study of the Liver, "EASL recommendations on treatment of hepatitis C 2018", J Hepatol, 69, pp.461~511 (2018)
- AASLD-IDSA HCV Guidance Panel, "Hepatitis C guidance 2018update : AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection", Clin Infect Dis, 67, pp.1477~1492 (2018)
- Jong Eun Yeon, "Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD", IDSA and 2016 EASL, 2018, pp.24(3), 278~293[DOI]
- "Draft Global Health Sector Strategies:Viral Hepatitis, 2016–2021" (2016)[URL]
- Hyung Joon Yim, "Elimination of hepatitis C: What would be the practical approach?", Clinical and Molecular Hepatology, 27(1), pp.97~99 (2021), 대한간학회[DOI]
- 이혜원, "Cost-effectiveness of chronic hepatitis C screening and treatment", Clinical and Molecular Hepatology, 28(2), pp.164~173 (2022), 대한간학회[DOI]
- Hye-Lin Kim, "A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective", Clinical and Molecular Hepatology, 28(1), pp.91~104 (2022), 대한간학회[DOI]
- Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
- Joon Yeul Nam, "Epidemiological and Clinical Characteristics of Hepatitis C Virus Infection in South Korea from 2007 to 2017: A Prospective Multicenter Cohort Study", Gut and Liver, 14(2), pp.207~217 (2020), 거트앤리버 소화기연관학회협의회
- Afdhal N, "Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection", N Engl J Med, 370, pp.1889~1898 (2014)
- Mizokami M, "Real-world safety and effectiveness of ledipasvir", sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan, 2021, pp.28, 129~141
- Oidov Baatarkhuu, "Efficacy and safety of ledipasvir", sofosbuvir in 5,028 Mongolian patients infected with genotype 1 hepatitis C virus: A multicenter study, 2021, pp.27(1), 125~135[DOI]
- Seong Hee Kang, "Outcomes of hepatitis C virus treatment with ledipasvir", sofosbuvir in Mongolian population: Successes and challenges facing scale-up of care, 2021, pp.27(1), 100~102[DOI]
- Mizokami M, "Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C : an open-label, randomised, phase 3 trial", Lancet Infect Dis, 15, pp.645~653 (2015)
- Lim YS, "A phase IIIb study of ledipasvir", sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus, 2016, pp.10, 947~955
- Asahina Y, "Twelve weeks of ledipasvir", sofosbuvir all-oral regimen for patients with chronic hepatitis C genotype 2 infection : integrated analysis of three clinical trials, 2020, pp.50, 1109~1117
- "Guidance for the treatment of hepatitis C virus infection in Korea" (2008)[URL]
- Omar Alshuwaykh, "Current and future strategies for the treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 27(2), pp.246~256 (2021), 대한간학회[DOI]
- Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)
- Saab S, "Safety and efficacy of ledipasvir", sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older, 2016, pp.63, 1112~1119
- Jensen CM, "Ledipasvir-sofosbuvir : a once-daily oral treatment option for chronic hepatitis C virus genotype 1 infection", Pharmacotherapy, 36, pp.562~574 (2016)
- Liu CH, "Comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting antiviral agents in hepatitis C patients in Taiwan", Aliment Pharmacol Ther, 48, pp.1290~1300 (2018)
- Backus LI, "Real-world effectiveness of ledipasvir", sofosbuvir in 4, 365treatment-naive, genotype 1 hepatitis C-infected patients, 2016, pp.64, 405~414
- Buggisch P, "Real-world effectiveness of 8-week treatment with ledipasvir", sofosbuvir in chronic hepatitis C, 2018, pp.68, 663~671
- Curry MP, "Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients", Aliment Pharmacol Ther, 46, pp.540~548 (2017)
- Kowdley KV, "Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis", N Engl J Med, 370, pp.1879~1888 (2014)
- Marcus JL, "No difference in effectiveness of 8 vs 12 weeks of ledipasvir and sofosbuvir for treatment of hepatitis C in black patients", Clin Gastroenterol Hepatol, 16, pp.927~935 (2018)
- Latt NL, "Eight-week ledipasvir", sofosbuvir in non-cirrhotic, treatment-naïve hepatitis C genotype-1 patients with hepatitis C virus-RNA < 6 million : single center, real world effectiveness and safety, 2017, pp.23, 4759~4766
- Reddy KR, "Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis : an integrated safety and efficacy analysis", Hepatology, 62, pp.79~86 (2015)
- Chen-Hua Liu, "Sofosbuvir", velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis, 2021, pp.27(4), 575~588[DOI]
- Berenguer M, "Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation", Hepatology, 32(4 Pt 1), pp.852~858 (2000)
- Kwok RM, "Sofosbuvir plus ledispasvir for recurrent hepatitis C in liver transplant recipients", Liver Transpl, 22, pp.1536~1543 (2016)
- Charlton M, "Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease", Gastroenterology, 149, pp.649~659 (2015)
- Grace Lai-Hung Wong, "Drug-drug interactions with direct-acting antivirals — less is more", Clinical and Molecular Hepatology, 27(1), pp.81~82 (2021), 대한간학회[DOI]
- Lawitz E, "Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment : a multicentre, phase 2b, non-randomised, open-label study", Lancet Gastroenterol Hepatol, 5, pp.918~926 (2020)
- Pockros PJ, "Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or endstage renal disease", Gastroenterology, 150, pp.1590~1598 (2016)
- Paul Kwo, "More evidence that direct acting antiviral therapy is safe and effective in cirrhosis and chronic kidney disease including peritoneal dialysis", Clinical and Molecular Hepatology, 26(4), pp.489~491 (2020), 대한간학회[DOI]
- "Sofosbuvir-based and elbasvir/grazoprevir treatment failures" (2021)[URL]